Regeneron Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Regeneron Pharmaceuticals Inc 公司

Regeneron Pharmaceuticals, Inc. 是一家綜合性生物技術公司。該公司發明、開發、製造和銷售用於治療嚴重疾病的藥物。其產品和正在開發的產品候選物旨在幫助患有眼部疾病、過敏和炎症性疾病、癌症、心血管和代謝疾病、神經系統疾病、血液病、傳染病和罕見疾病的患者。該公司通過其 VelociSuite 技術（例如 VelocImmune，它使用基因人源化小鼠生產優化的全人抗體和雙特異性抗體）以及通過 Regeneron Genetics Center 等雄心勃勃的研究計劃，幫助加速和改進傳統的藥物開發流程。其上市產品包括 EYLEA（阿柏西普）注射液；Dupixent（dupilumab）注射液；Libtayo（cemiplimab）注射液；Praluent（alirocumab）注射液；Kevzara（sarilumab）注射液等。

公司簡介

公司代碼REGN

公司名稱Regeneron Pharmaceuticals Inc

上市日期Apr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

員工數量15106

證券類型Ordinary Share

年結日Apr 02

公司地址777 Old Saw Mill River Road

城市TARRYTOWN

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編10591

電話17813705000

網址https://www.regeneron.com/

公司代碼REGN

上市日期Apr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

名稱

名稱/職務

職務

持股

持股變動

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

其他

266.30M

8.79%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

其他

266.30M

8.79%

股東統計

更新時間: 8月30日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

其他

74.12%

持股股東

佔比

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

其他

74.12%

股東類型

持股股東

佔比

Investment Advisor

47.67%

Investment Advisor/Hedge Fund

28.51%

Hedge Fund

5.34%

Research Firm

2.70%

Pension Fund

2.54%

Bank and Trust

2.15%

Individual Investor

2.01%

Sovereign Wealth Fund

1.22%

Insurance Company

0.08%

其他

7.78%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

9.36M

8.81%

+117.55K

+1.27%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.74M

5.41%

+45.93K

+0.81%

Mar 31, 2025

State Street Global Advisors (US)

4.79M

4.51%

-42.58K

-0.88%

Mar 31, 2025

Dodge & Cox

2.32M

2.19%

+2.77K

+0.12%

Mar 31, 2025

Fidelity Management & Research Company LLC

7.40M

6.97%

-573.19K

-7.19%

Mar 31, 2025

Capital International Investors

3.99M

3.76%

-747.80K

-15.79%

Mar 31, 2025

JP Morgan Asset Management

4.08M

3.84%

-1.16M

-22.19%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.47M

2.33%

+41.95K

+1.73%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

2.19M

2.07%

-36.81K

-1.65%

Jun 30, 2025

Putnam Investment Management, L.L.C.

1.91M

1.8%

+285.04K

+17.50%

Mar 31, 2025

持股ETF

更新時間: 9月6日週六

機構名稱

佔比

Amplify Weight Loss Drug & Treatment ETF

7.43%

Simplify Health Care ETF

7.25%

Invesco Nasdaq Biotechnology ETF

6.57%

ProShares Ultra Nasdaq Biotechnology

6.13%

iShares Biotechnology ETF

5.83%

VanEck Biotech ETF

5.37%

iShares Genomics Immunology and Healthcare ETF

4.74%

First Trust NYSE Arca Biotechnology Index Fund

3.43%

First Trust NASDAQ Pharmaceuticals ETF

3.36%

iShares US Tech Breakthrough Multisector ETF

2.99%

Amplify Weight Loss Drug & Treatment ETF

佔比7.43%

Simplify Health Care ETF

佔比7.25%

Invesco Nasdaq Biotechnology ETF

佔比6.57%

ProShares Ultra Nasdaq Biotechnology

佔比6.13%

iShares Biotechnology ETF

佔比5.83%

VanEck Biotech ETF

佔比5.37%

iShares Genomics Immunology and Healthcare ETF

佔比4.74%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.43%

First Trust NASDAQ Pharmaceuticals ETF

佔比3.36%

iShares US Tech Breakthrough Multisector ETF

佔比2.99%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Regeneron Pharmaceuticals Inc

575.060USD

Regeneron Pharmaceuticals Inc

575.060

概覽

公司

財務

分析